The Netherlands' cannabis pilot is showing early improvements in regulated supply and track and trace systems, but packaging, potency guidance, hash availability, and consumer information still need work. The experiment offers a rare look at what happens when an established tolerated retail market attempts to convert its entire supply chain into a regulated system.

The United States has one of the world's largest cannabis markets but remains a minor participant in international medical cannabis trade. Federal medical rescheduling could create new opportunities, but U.S. operators still face established foreign competitors, pharmaceutical quality standards, permitting requirements, logistics costs, and growing domestic production in importing markets.

Canada remains the world's largest medical cannabis exporter, but growing European production is beginning to challenge its lead. Germany's expanding market, Portugal's rapid export growth, stricter pharmaceutical standards, reimbursement changes, and new lower cost suppliers are reshaping international cannabis competition.

Canada still supplies most of Australia's imported medical cannabis, but Thailand rapidly gained market share in 2025 while Australian domestic production reached a new high. The shift shows an increasingly competitive supply chain where pricing, quality standards, contracts, inventory, and reliable international market access matter more.

Morocco’s legal cannabis industry now has more than 140 cannabis based products manufactured and officially registered with the Moroccan Agency for Medicines and Health Products. The bigger lesson is that Morocco is moving from cultivation potential into regulated product manufacturing, export readiness, and international supply chain relevance.

AGLC is moving Alberta toward a consignment distribution model that would let suppliers keep ownership of cannabis inventory while products sit in the provincial warehouse. The bigger lesson is that supply chain reform can improve flexibility, but it can also shift payment timing, inventory risk, and working capital pressure onto suppliers.

Emblem Cannabis is set to acquire Ayurcann assets, including vape and pre roll manufacturing capacity, a Health Canada licensed facility, and national distribution relationships. The bigger lesson is that Canadian cannabis consolidation is still being driven by tax pressure, debt, wholesale compression, and distressed asset strategy.

Interstate cannabis commerce could create a major opening for prepared medical only operators, but it could also expose smaller businesses to price pressure, mismatched track and trace systems, uneven lab standards, labeling issues, and litigation risk.

Vireo Growth bought its New York cultivation and production complex for $88.5 million and announced a $40 million Bridgewell Agribusiness deal. The bigger lesson is that cannabis operators are moving beyond license accumulation into real estate control, supply chain control, and distressed asset strategy.

A new GCNC and Whitney Economics report examines how pricing compression is reshaping cannabis markets across North America, Europe, Latin America, and Israel. The bigger lesson is that emerging markets can look attractive early, but operators and investors need to model margin pressure before supply expands and prices fall.